1. In Vitro Diagnostics: Chalenge and Change Ahead In Vitro Diagnostics Challenge and Change Ahead The Medtech Marketplace 31 January 2007 Shara Rosen, RT, MBA Senior Analyst Kalorama Information New York, New York

2. In Vitro Diagnostics: Chalenge and Change Ahead The IVD Market 2005-2010 7% Annual Growth

3. In Vitro Diagnostics: Chalenge and Change Ahead High-Growth IVD Areas Revenues (in millions) AAGR 20052010 Infectious Diseases $2,050$3,1509% Tumor markers 6259809% Cardiac markers 7159305% Autoimmune 25041010% Diabetes/HbA1c 19032011% FISH 25070023% SNPs/Oncology 18560027% PGx 5020032% Flow Cytometry 7501,58016% POC, OTC diabetes 6,5009,8609% Immunoassays Nucleic Acid Assays

4. In Vitro Diagnostics: Chalenge and Change Ahead Healthcare Delivery Trends and IVDs The role of IVDs in the post genomics era Healthcare decentralization The impact of disease management The role of IVDs in patient management

5. In Vitro Diagnostics: Chalenge and Change Ahead GE Healthcare Amersham, Abbott Siemens Bayer Diagnostics, DPC Proctor & Gamble Inverness Schering Plough OraSure Philips Medical Systems BG Medicine Devices and Diagnostics Make for Innovation

6. In Vitro Diagnostics: Chalenge and Change Ahead Thank You Shara Rosen, RT, MBA Senior Analyst Kalorama Information a division of MarketResearch.com, Inc. 38 East 29 th Street, 6 th Floor New York, New York 10016 srosen@kaloramainformation.com www.KaloramaInformation.com srosen@kaloramainformation.com www.KaloramaInformation.com